MyoGene Bio

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
MyoGene Bio is a biotechnology startup dedicated to improving the lives of patients with muscle disease through the development of cutting-edge therapies. Our first product is a gene editing therapy designed to permanently restore the dystrophin protein which is otherwise lacking in Duchenne muscular dystrophy. This therapy is expected to significantly improve function and lifespan, applicable for ~50% of Duchenne patients. MyoGene Bio has been awarded 3 grants totaling $2M and is currently seeking additional funding to carry out further preclinical studies.
Speaker
photo
Co-founder and CEO
MyoGene Bio